Sphera Funds Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Sphera Funds Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-271,792	Closed	-$1.81M	–	128
2025 Q1	$1.81M	Hold	271,792	–	–	0.42%	73
2024 Q4	$3.42M	Buy	271,792 +40,000	+17%	+$602K	0.62%	63
2024 Q3	$4.28M	Buy	231,792 +24,859	+12%	+$509K	0.68%	48
2024 Q2	$4.46M	Buy	206,933 +23,211	+13%	+$533K	0.61%	53
2024 Q1	$4.95M	Sell	183,722 -7,061	-4%	-$201K	0.7%	50
2023 Q4	$5.72M	Sell	190,783 -18,257	-9%	-$403K	0.92%	43
2023 Q3	$4.28M	Sell	209,040 -26,960	-11%	-$490K	0.78%	47
2023 Q2	$4.69M	Hold	236,000	–	–	0.73%	53
2023 Q1	$4.04M	Buy	+236,000	New	+$4.62M	0.68%	50
2021 Q1	–	Sell	-75,000	Closed	-$4.11M	–	196
2020 Q4	$4.11M	Sell	75,000 -153,016	-67%	-$5.58M	0.37%	76
2020 Q3	$5.21M	Sell	228,016 -112,000	-33%	-$2.76M	0.51%	57
2020 Q2	$7.12M	Buy	340,016 +5,000	+1%	+$90.1K	0.67%	40
2020 Q1	$4.67M	Sell	335,016 -26,872	-7%	-$532K	0.58%	38
2019 Q4	$8.24M	Sell	361,888 -298,112	-45%	-$4.98M	0.68%	26
2019 Q3	$7.69M	Buy	660,000 +350,000	+113%	+$4.34M	1.19%	20
2019 Q2	$4.65M	Buy	310,000 +19,999	+7%	+$349K	0.64%	48
2019 Q1	$5.09M	Hold	290,001	–	–	0.46%	49
2018 Q4	$4.3M	Buy	+290,001	New	+$4.81M	0.48%	47
2018 Q3	–	Sell	-34,475	Closed	-$677K	–	127
2018 Q2	$677K	Sell	34,475 -267,800	-89%	-$5.07M	0.09%	95
2018 Q1	$5.67M	Buy	302,275 +277,165	+1,104%	+$4.52M	0.86%	36
2017 Q4	$1.05M	Sell	25,110 -75,331	-75%	-$747K	0.12%	112
2017 Q3	$715K	Hold	100,441	–	–	0.1%	106
2017 Q2	$763K	Hold	100,441	–	–	0.13%	108
2017 Q1	$804K	Hold	100,441	–	–	0.16%	96
2016 Q4	$2.45M	Hold	100,441	–	–	0.62%	49
2016 Q3	$3.81M	Buy	100,441 +37,941	+61%	+$1.19M	0.62%	41
2016 Q2	$1.86M	Hold	62,500	–	–	0.48%	63
2016 Q1	$1.85M	Sell	62,500 -27,500	-31%	-$825K	0.4%	56
2015 Q4	$4.08M	Buy	90,000 +16,250	+22%	+$708K	0.6%	32
2015 Q3	$2.77M	Sell	73,750 -21,250	-22%	-$976K	0.35%	68
2015 Q2	$1.86M	Sell	95,000 -5,000	-5%	-$111K	0.18%	111
2015 Q1	$2.17M	Buy	+100,000	New	+$2.35M	0.23%	101

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Sphera Funds Management's RCKT Position: Q2 2025 in Review

Sphera Funds Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 271,792 shares — an estimated $1.81M sold.

Sphera Funds Management first reported a position in RCKT in Q1 2015 and held it in 32 quarters. The position peaked at $8.24M in Q4 2019. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

Sphera Funds Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Sphera Funds Management sold 271,792 Rocket Pharmaceuticals shares in Q2 2025, an estimated $1.81M.
Sphera Funds Management first reported a position in Rocket Pharmaceuticals in Q1 2015 and held it in 32 quarters.
Sphera Funds Management's Rocket Pharmaceuticals position peaked at $8.24M in Q4 2019.
196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.